LY3114062 IV
Phase 1Small molecule
Eli LillyLY3114062 IV is one of 35 small molecule programs targeting Arthritis. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
159 competitors in Arthritis
#DrugCompanyPhaseTrials
1Cosentyx
NovartisPhase 3
Taltz
Eli LillyPhase 3
Stelara
Johnson & JohnsonPhase 3
Bimzelx
UCBPhase 3
Ilaris
NovartisPhase 3
Kenalog
BBassett Healthcare
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Tanezumab
PfizerPhase 3
AIN457
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY3114062 IV. EMBL-EBI & Wellcome Sanger Institute.
- [4]